# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Suraj Kalia downgrades ResMed (NYSE:RMD) from Outperform to Perform.
ResMed stock is trading lower Monday after Eli Lilly and Company released data from a clinical trial in regards to the treatmen...
Wall Street faces a continuation of last week’s trend during Monday’s morning trading, with semiconductor stocks selling off he...
Citigroup analyst Mathieu Chevrier downgrades ResMed (NYSE:RMD) from Buy to Neutral.
The U.S.
Needham analyst Mike Matson reiterates ResMed (NYSE:RMD) with a Buy and maintains $236 price target.